Tue.Apr 23, 2024

article thumbnail

Novartis nominates former Bristol Myers CEO Giovanni Caforio as its new chair. Will M&A deals follow?

Fierce Pharma

Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025.

Pharma 349
article thumbnail

FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery

MedCity News

ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News.

FDA 128
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate

Fierce Pharma

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. But thanks to blockbuster meds across wider disease areas and other challenges, the lucrative market may soon slow down for the first time in years.

Marketing 330
article thumbnail

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

pharmaphorum

After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product

FDA 122
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor use

Fierce Pharma

Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, the newcomer boasts an FDA approval covering a broader patient population. | Another drug is in town for common pediatric brain tumors. Compared with an incumbent offering from Novartis, Day One's newcomer boasts an FDA approval covering a broader patient population.

FDA 305
article thumbnail

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

pharmaphorum

Novartis has proposed ex-BMS CEO Caforio as the successor to chair Joerg Reinhardt when he steps down next year, as it posts a strong set of Q1 results

111
111

More Trending

article thumbnail

Don’t Let Inflation Bloat Your Drug Spending

MedCity News

Smart but easy tech upgrades can boost margins. The post Don’t Let Inflation Bloat Your Drug Spending appeared first on MedCity News.

110
110
article thumbnail

Eli Lilly inks deal to acquire Nexus manufacturing plant in WI as Mounjaro and Zepbound shortages drag on

Fierce Pharma

As doctors and patients in the U.S. | As doctors and patients in the U.S. grapple with widening shortages of the popular diabetes therapy Mounjaro and its obesity counterpart Zepbound, the maker of the tirzepatide drugs, Eli Lilly, is forging ahead on its quest to expand capacity for its injectable medicines.

Doctors 264
article thumbnail

Neurodivergent Masking: A Hidden Contributor to the $2-Trillion Burnout Crisis

MedCity News

It can be tiring pretending to be someone you’re not. For many neurodivergent people at work, this is an everyday reality — and it’s burning them out. The post Neurodivergent Masking: A Hidden Contributor to the $2-Trillion Burnout Crisis appeared first on MedCity News.

109
109
article thumbnail

Novartis 'actively' reviewing relationships with Chinese contractors amid US biosecurity crackdown: CFO

Fierce Pharma

As the BIOSECURE Act threatens to upend relationships with Chinese contractors and western biopharma companies operating in the U.S., Novartis has elected not to adopt a “wait and see” attitude.

Biopharma 264
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Collaboration Now: Maximizing AI’s Potential in the Industry it Matters Most

MedCity News

No passing fad, AI in healthcare is here, and it’s already improving the lives of patients, healthcare workers, and researchers. How can we make a good thing even better? The post Collaboration Now: Maximizing AI’s Potential in the Industry it Matters Most appeared first on MedCity News.

article thumbnail

Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs

Fierce Pharma

Novartis has increased its full-year sales guidance after pulling off a strong first quarter, even though three meds missed analysts’ expectations ahead of their key expansion opportunities. | Novartis has increased its full-year sales guidance after pulling off a strong first quarter, even though three cancer drugs missed analysts’ expectations ahead of their key expansion opportunities.

Sales 242
article thumbnail

EU approves Pfizer antibiotic for superbug infections

pharmaphorum

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat serious infections caused by MDR Gram-negative bacteria in adults.

104
104
article thumbnail

Vertex jumps to TreeFrog to enhance production of Type 1 diabetes cell therapy candidates

Fierce Pharma

Following success in cystic fibrosis and sickle cell disease, Vertex’s next big leap is Type 1 diabetes (T1D). | Following success in cystic fibrosis and sickle cell disease, Vertex’s next big leap is Type 1 diabetes. the Boston company develop three pipeline candidates in the indication will be French cell therapy developer and manufacturer TreeFrog Therapeutics.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

ReferralMD Expands Digital Front Door with Conversational AI Patient Registration & Intake

Referral MD

ReferralMD, a leader in healthcare technology solutions, is excited to announce the expansion of its Digital Front Door offering using the latest innovation in conversational AI. The Patient Registration & Intake Solution, powered by conversational AI, reimagines how patients engage with healthcare providers. With the healthcare technology market becoming more competitive than ever, ReferralMD differentiates itself with its comprehensive platform, including Digital Front Door, eConsults, R

Patients 104
article thumbnail

Sanofi’s oral BTK programme gets back on track

pharmaphorum

Phase 3 readout allows Sanofi to prepare US and EU filings for oral BTK inhibitor rilzabrutinib in immune thrombocytopenia (ITP), its first indication

102
102
article thumbnail

LogiPharma Europe 2024: LogiPharma Commercial Director Discusses Themes of the Show

Pharmaceutical Commerce

In an interview with Pharma Commerce Associate Editor Nicholas Saraceno, Will Robinson, Commercial Director, LogiPharma, talks themes of this year's event and future plans for the show.

Pharma 101
article thumbnail

EC approves Pfizer’s Emblaveo for multidrug-resistant infections

Pharmaceutical Technology

The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.

Marketing 101
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Pharma Pulse 4/23/24: Meta Places Smart Assistants Across Its Apps, Burden of Pneumococcal Disease Consistent Across Age Groups & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 101
article thumbnail

Shakeup at BenevolentAI continues with job, programme cuts

pharmaphorum

BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third quarter of 2025.

101
101
article thumbnail

Navigating an Uncertain Regulatory Environment for mRNA-based Products

PharmaTech

Regulations for mRNA products are evolving as the market for mRNA expands.

article thumbnail

BMS inks CAR T cell therapy manufacturing deal with Cellares

European Pharmaceutical Review

Bristol Myers Squibb (BMS) and Cellares have announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. The deal is valued at up to $380 million in upfront and milestone payments. The agreement will see BMS use Cellares’ fully automated cell therapy manufacturing platform for the clinical and commercial-scale manufacturing of select CAR T cell therapies.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Trial reveals mechanisms that contribute to impact of malnutrition and HIV infection

PharmaTimes

Severe acute malnutrition is responsible for nearly half of all child deaths globally and affects 17 million children annually

Medical 92
article thumbnail

Inside J&J’s strategy to de-gender clinical trials

PharmaVoice

Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.

Medical 81
article thumbnail

Boehringer Ingelheim and Ochre Bio partner on liver disease in deal worth over $1bn

PharmaTimes

Chronic liver disease and associated cirrhosis account for one million deaths every year

92
article thumbnail

Why Headspace Is Launching Direct-to-Consumer Services

MedCity News

Headspace is going toe-to-toe with the likes of Talkspace and BetterHelp by bringing its mental health services directly to consumers — starting with text-based mental health coaching. The post Why Headspace Is Launching Direct-to-Consumer Services appeared first on MedCity News.

75
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA Approves Ankiva Plus Bacillus Calmette-Guérin For Non-Muscle Invasive Bladder Cancer

Pharmacy Times

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

FDA 59
article thumbnail

Salesperson Development Hinges on A Clear Plan and Supportive Culture

Integrity Solutions

High-performing Sales organizations go beyond hiring for “measurables” and have well thought out plans, processes, coaching and salesperson development strategies in place. The annual NFL Draft is always full of intrigue for many reasons. The real-time drama unfolds as teams select what they consider to be the best 256 college football prospects over a three-day period.

Sales 57
article thumbnail

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

Pharmacy Times

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

article thumbnail

Accessing Hard-to-Reach Healthcare Professionals with Ease in BC

Scott’s Directories

Connecting with healthcare professionals in British Columbia (BC) can be a challenging task, especially given the vast and diverse regions of the province. Sales and marketing teams aiming to target physicians, surgeons, and other healthcare providers often face significant obstacles in reaching their prospects effectively. However, leveraging a comprehensive BC physician directory can transform this daunting task into a streamlined and efficient process.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A